Antivirals: Difference between revisions

Line 25: Line 25:
**[[Emtricitabine/tenofovir]] (Truvada) + raltegravir
**[[Emtricitabine/tenofovir]] (Truvada) + raltegravir
**[[Emtricitabine/tenofovir]] + dolutegravir
**[[Emtricitabine/tenofovir]] + dolutegravir
**Abacavir/lamivudine( (Epzicom) + dolutegravir OR abacavir/lamivudine/dolutegravir (Triumeq)
**Abacavir/lamivudine (Epzicom) + dolutegravir OR abacavir/lamivudine/dolutegravir (Triumeq)
**[[Emtricitabine/tenofovir]]/elvitegravir/cobicistat (Stribild)
**[[Emtricitabine/tenofovir]]/elvitegravir/cobicistat (Stribild)
**[[Emtricitabine/tenofovir]] + ritonavir + darunavir
**[[Emtricitabine/tenofovir]] + ritonavir + darunavir

Revision as of 01:24, 26 February 2017

Anti-herpetic agents

Anti-influenza agents

Adamantane Derivatives

Neuraminidase Inhibitors

Interferons

HAART

  • HIV regimen that typically consists of combination of 2 nucleoside and/or non-nucleoside reverse transcriptase inhibitors PLUS a protease inhibitor, reverse-transcriptase inhibitor, or integrase inhibitor
  • US DHHS first-line regimens
  • WHO first-line regimen

Other

See Also

External Links

References